Document is current
Any future updates will be listed below
-
Authors
Woods, Allison T
Murray, Abner A
Vincent, Benjamin G https://orcid.org/0000-0002-1762-2282
Akulian, Jason https://orcid.org/0000-0002-4528-8496
Pecot, Chad V https://orcid.org/0000-0002-5250-2999
-
Funding
Funding for this research was provided by:
HHS | NIH | NCI | Division of Cancer Prevention, National Cancer Institute (R01CA215075)
HHS | NIH | NCI | Division of Cancer Prevention, National Cancer Institute (1R01CA279532)
HHS | NIH | NCI | Division of Cancer Prevention, National Cancer Institute (1R41CA246848)
HHS | NIH | NCI | Division of Cancer Prevention, National Cancer Institute (1R44-CA28493)
Lung Cancer Initiative of North Carolina Research Fellowship (NIH NIGMS T32GM086330)
Lung Cancer Initiative of North Carolina Research Fellowship (NCI T32CA285257)
- License Information
-
More Information
Article History
Received: 27 October 2025
Revised: 10 November 2025
Accepted: 13 November 2025
First Online: 9 January 2026
Disclosure and competing interests statement
: CVP is a founder and shareholder in EnFuego Therapeutics. BGV is a co-founder and shareholder in Pathfinder Oncology and ShieldBreak Bio. AW, AAM, and JA declare no conflicts of interest.
